Nivolumab is particularly beneficial for patients with advanced or metastatic RCC who have previously undergone anti-angiogenic therapy. The results from CheckMate 025 indicate that patients with intermediate or poor risk factors might derive more pronounced benefits from nivolumab, making it a critical option for this subgroup.
